Brain tumors consist of different tumor entities. Identification of genetic alterations and molecular determinants of susceptibility to treatment will define tumor entities, decrease the side effects and will bring tangible economic benefits by reducing high costs of therapy. Our project addresses several urgent needs: we will help make precision medicine a reality for patients and clinicians by providing molecular diagnostics using DNA targeted and RNA sequencing to help to match their patients to targeted therapies;we will cooperate with drug developers and cancer researchers to identify novel targets and assist in development of targeted cancer therapies. In frame of the new NGS Platform for neuro-oncology we employ our unique experience in identification of brain tumor-related genes and working in collaboration with neuroncologists we will provide molecular diagnostics and an updated information about new types of treatments, clinical trials and local initiatives.